VSCR is an non-profit educational institute and registered in Austria as "gemeinnützige GmbH".

Ernst Agneter, MD, PhD, MBA
Vienna / AT

Ernst Agneter, MD, PhD, MBA

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Head of Center for Pharmacological Medicine, Sigmund Freud Medical University Vienna

Managing Director, Agneter PharmaConsulting GmbH, Chairman of the Pharmig working group Health Economics & Reimbursement of Executive Board of Pharmig, Association of the Austrian Pharmaceutical Industry

Ernst Agneter is a specialist in pharmacology and toxicology. After receiving his PhD in 1989, he worked as a doctor of general medicine for the Ministry of Health in the area of drug approvals and as assistant at the Pharmacological Institute of the University of Vienna. In 2000, he obtained the teaching license for pharmacology and toxicology. In 2018 he was appointed to the Chair of Pharmacology of the Sigmund Freud Private University in Vienna. In addition, he holds a Master of Advanced Studies, a Master of Business Administration and an Examination in Wholesale Medicines and Poisons. Agneter served as Medical and Marketing Director in an international pharmaceutical company, as well as an external expert of the Federal Ministry for Social Security and Generations, and as a member of the EMEA experts nominated by Austria, as well as peer reviewers. In 2001, he founded the Agneter PharmaConsulting GmbH with a focus on the preparation of preclinical and clinical expert reports, evaluation of pharmaceuticals as well as pricing and reimbursement of proprietary medicinal products.

Lieven Annemans
Lieven Annemans
Ghent / BEL

Lieven Annemans

Lieven Annemans

Ghent / BEL

Health Economy and Health Technology Assessment (HTA)

Lieven Annemans is a Senior Professor of Health Economics at the Faculty of Medicine at Ghent University, Belgium. He has 20 years of experience in international health economics research. For many years he is a well sought expert consultant and lecturer in health technology assessment (HTA). He was advisor to the Belgian Minister of Health from 2001 to 2003 and president of the Flemish health council from 2003 to 2009. He is Past-President of ISPOR (International Society of PharmacoEconomics and Outcomes Research). He published more than 250 papers and several books on health economics and HTA.

Anna Bucsics MD
Vienna / AT

Anna Bucsics MD

Vienna / AT

Health Economy and Health Technology Assessment (HTA)

Former department Head, Department of pharmaceutical Affairs, Federation of Austrian Social Insurance Institutions

MoCA Project Advisor since 2016. Lecturer at the Vienna School of clinical Research. Expert panel member of the Austrian Federal Administrative Court Member of the European Commission Experts Group on Rare Diseases. External Lecturer at the Department of Finance, University of Vienna

Advisor to the MEDEV Committee (an informal group of representatives and experts from payer institutions in Europe), Participation in European projects such as EUnetHTA, the High Level Pharmaceutical Forum, the Platform on Access to Medicines in Europe (in the working groups on access to biosimilars and orphan medicinal products), and Parallel Scientific Advice at EMA.

Department Head for the Main Association of Austrian Social Insurance Institutions (MAASSI) until the end of 2013. Previously, auditor for pharmaceutical expenditures at the Viennese Social Health Insurance and as pharmacological consultant for MAASSI

Training in internal medicine in Graz, diploma as a specialist for Pharmacology and Toxicology.

Medical degree from the Karl-Franzens-University of Graz, Austria, postgraduate research work in neuropharmacology at the Department of Experimental and Clinical Pharmacology.

Dominique Dubois
Dominique Dubois
Brussels / BE

Prof. Dr. med. Dominique Dubois

Dominique Dubois

Brussels / BE

Health Economy and Health Technology Assessment (HTA)

Dominique Dubois MD FBCPM FFPM

Physician Specialist in Pharmaceutical Medicine. Lecturer in Pharmacoeconomics & Patient Reported Outcomes Research. Vice-Chairman PHARMED PharmaTrain Centre of Excellence. Author of >50 publications in peer-reviewed journals. Specialty Chief Editor of Frontiers in Pharmaceutical Medicine and Outcomes Research.

Dominique contributed to the FDA PRO draft guidance, the EMEA reflection paper on HRQL measures, and an expert guidance report on coverage decision-making in orphan diseases. He was also largely instrumental in achieving a successful NICE Single Technology Appraisal.

Jürgen Raths
Geneva / CH

Jürgen Raths

Geneva / CH

Health Economy and Health Technology Assessment (HTA)

Dr. Raths studied medicine and dentistry at the Universities of Heidelberg, Bonn and Cologne. He obtained his Doctorate in Medicine at the University of Bonn. He is MD with 30 years of experience in the European and global pharma business, with positions held in clinical research, medical, marketing, sales and General Management in Europe and the USA. Jürgen served as CEO in assignments in public and private specialty pharma companies. Jürgen is Managing Director of Cordée Consulting in Geneva and supports innoplexus, a German-Indian Big Data and Artificial Intelligence company as Head of Life Sciences. He has leadership experience in: general management, company creation, M&A, change management and corporate restructuring situations, as well as in global business development.

Keith Tolley
Keith Tolley
Buxton / UK

Keith Tolley

Keith Tolley

Buxton / UK

Health Economy and Health Technology Assessment (HTA)

Keith’s background is primarily in health economics and health technology assessment. He has worked both in academia (University of York – Centre for Health Economics and University of Nottingham, UK 1987-1997) and for several pharmaceutical companies, including GSK, Pfizer and Ortho Biotech (1997-2005) and in consultancy as a Director at Mapi Values.  Keith is now  Director of Tolley Health Economics, a company he set up in 2008 to provide strategic advice and consultancy in the area of the use of health economic analysis and HTA methods to support the market access of pharmaceuticals.  Keith has direct experience of health technology assessment as performed by NICE for England and Wales and the SMC in Scotland, and reimbursement and pricing issues around Europe. Keith provides strategic advice and consultancy on company submissions to NICE and SMC across a range of disease areas. He has also reviewed and been involved in the development of health economic models for NICE/SMC and other HTA bodies, and has reviewed economic models for their suitability (e.g. structure, data inputs) for drug reimbursement purposes.

Keith is also a health economics assessor with the Scottish Medicines Consortium (the HTA body advising on new drug reimbursement in Scotland), a position he has had since 2005, having previously been an industry representative on the NDC.  In 2013 Keith also became an assessor for the All Wales Medicine Strategy Group and has provided expert advice as part of the NICE Early Scientific Advise Programme.  Keith has published extensively in health economics and is the author of two books and several edited books.  Keith has a BA and an MPhil from the University of Leeds.